concern view manag
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
johnson johnson stand alon leader across major
base develop research pipelin except cash flow
gener togeth creat wide econom moat
 hold leadership role divers healthcar segment
includ medic devic over-the-count product sever
pharmaceut market contribut close total
revenu pharmaceut divis boast sever industry-lead
drug includ immunolog drug remicad psoriasi drug
stelara medic devic group bring almost one third
sale compani hold control posit mani
area includ orthoped ethicon endo-surgeri surgic
devic consum divis larg round remain
busi line despit manufactur issu past
sever year group still hold mani brand strong price
research develop effort result next-gener
product pharmaceut group recent launch sever
new blockbust howev rel compani size
need increas number meaning drug late-stag
develop support long-term growth compani also
minim invas surgic tool
expenditur sale strong cash gener
enabl firm increas dividend past half
centuri expect continu also allow take
advantag acquisit opportun augment growth
divers oper segment coupl expect new product
insul compani patent loss rel
pharma firm contrast peer face
major near-term patent loss hard-to-mak
complex drug like slow gener competit
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
johnson johnson world largest divers healthcar
compani three divis make firm pharmaceut medic devic
diagnost consum drug devic group repres close
sale drive major cash flow firm drug
divis focus follow therapeut area immunolog oncolog
neurolog pulmonari cardiolog metabol diseas devic
segment focus orthoped surgeri tool vision care
smaller area last segment consum focus babi care beauti
oral care over-the-count drug women health geograph
close half total revenu gener unit state
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
litig concern view manag
johnson johnson report third-quart result
slightli ahead consensu expect
dont see major impact fair valu estim
base out-performance continu view stock
fairli valu also firm wide moat look intact
shown steadi result across js key divis
fundament quarter look solid
continu face increas litig concern see
lawsuit manag factor
billion cost relat litig next five
year particular believ litig around side
effect opioid talc repres larger
settlement legal challeng neurosci drug
risperd compani pelvic mesh like lead
smaller settlement overal project legal cost
next five year similar previou five
year discount cash flow valuat
perspect market sentiment perspect actual
payout legal challeng past havent significantli
affect js stock price long term howev
case especi initi rule signific
turn quarter drug divis continu lead
overal growth devic consum group
improv despit gener competit drug group
recent launch continu off-set patent loss
especi oncolog immunolog expect
continu steadi growth drug unit next five
year expect steadi growth devic segment
potenti room upsid base new robot devic
reach market next two year
consum dont expect much acceler growth
base competit internet distribut channel
brand strength look less power
 continu make solid stride advanc drug
portfolio expand indic current
market drug bring new drug market
complet review pipelin pleas see annual
drug pipelin report moat remain secur innov
counter price gener headwind
increas fair valu estim
per share base increas project recent
drug hold strong price power typic reach
market shorter develop time overal within
core driver cash flow new immunolog oncolog
drug drive growth includ actelion acquisit
expect annual earn per share growth averag
next five year strong growth new
pipelin drug off-set patent loss
margin
next sever year wane
cost-remedi effort consum group
increas cost-contain effort throughout firm
help off-set margin pressur due loss patent
protect sever high-margin drug
immunolog drug remicad also follow
expect reduc depend asset sale
firm use occasion boost overal earn
larg basi low volatil cash flow
divers inelast product portfolio rate johnson
 johnson uncertainti low scenario analysi
assum base-cas fair valu estim bull
case probabl bear case
probabl project fair valu estim rel
base case scenario analysi show minor varianc
henc low fair valu uncertainti rate key factor
affect scenario analysi includ degre
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
compani overli depend one particular oper
segment pharmaceut busi medic devic
group consum product repres
total sale respect addit within
segment one product domin sale lipitor
despit carri lower-margin divis
maintain strong price power post gross
margin past five year valid
strong competit posit
johnson johnson effort support robust revenu
base pharmaceut compani recent launch
sever new blockbust allow johnson
johnson escap larg unscath upcom patent
expir effort medic devic includ
minim invas surgic tool help maintain
leadership sever medic devic area well
remain high sever devic product
exampl physician switch vendor hip knee
devic could take week month learn new
product keep physician tie compani
consum side new product
advanc combin solid brand power
reinforc market campaign sustain solid
compani face manag patent loss next
year price power core franchis
rel stabl turn macro environ
compani face sever headwind make solid
strateg move address challeng neg
side risk-sensit food drug administr
gener approv safe drug drug
high-ne area cancer also managed-car
pharmaci benefit manag consolid past
decad use grow size demand
success drug pipelin along magnitud
market pressur current market drug
importantli potenti pressur remicad
biosimilar unknown regulatori impact on-going
litig surround devic talc powder also weigh
certainti
believ johnson johnson carri one widest
moat healthcar sector support intellectu
properti drug group switch cost devic
segment strong brand power consum group
compani divers revenu base strong pipelin
robust cash flow gener creat wide econom
candid smaller biotechnolog compani look
partner new drug strengthen johnson
johnson abil bring new product market
johnson johnson divers oper major pillar
support wide moat compani hold leadership
role number segment includ medic devic
over-the-counter medicin sever drug market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
lower drug price reduc coverag less innov
drug forc drug firm push true innov
reduc power compani distribut network
 govern evalu compar
effect program aggress price
negoti rais bar futur innov
johnson johnson face sever headwind pipelin
focus innov treatment area unmet
medic area oncolog immunolog
payer coverag price power remain strong outsid
pipelin strong entrench medic devic
consum good give firm relief
pressur pharmaceut group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oth major near-term patent loss
product hard manufactur
ojnj late-stag drug pipelin rel weak
size compani could creat long-term
hurdl growth
odivers healthcar segment help insul
downturn economi offer defens
growth opportun steadi like grow
osever johnson johnson key drug
pipelin drug specialti drug tend carri
strong price power well lower regulatori
hurdl approv
oleg action regard product recal hip knee
replac along sever consum product
could damag compani brand power cost
billion dollar creat distract
osever johnson johnson import drug
face increas competit could slow
growth rate drug group
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
johnson johnson hold one strongest financi
posit healthcar sector project
debt/ebitda recent acquisit
actelion put dent compani cash balanc
annual free cash flow close billion
compani sound financi shape even expect
bolt-on acquisit share repurchas
compani remain solid financi foot
oper standpoint patent loss mitig sever
divers oper line medic devic consum
product cash flow remain rel stabl
addit expect share repurchas next
sever year draw share count
johnson johnson need overcom sever roadblock
product metal-on-met hip knee implant
sever product recal could damag sterl
reput longer term compani face typic
healthcar risk reduc price power
govern pharmaci benefit manag regulatori
delay nonapprov well increasingli aggress
gener competit small-molecul drug
biolog particular biosimilar risk remicad
increas sever biosimilar work gain
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
overal view stewardship johnson johnson
rel standard firm good record
make sound capit deploy decis
consist gener return invest capit
cost capit major recal recent potenti
overpay actelion poor turnaround time
address manufactur problem certain key divis
lead us balanc view compani
weldon step top posit
lead johnson johnson sinc given
weldon age rigor process find successor
see chang leadership red flag gorski
bring strong record industri experi date back
began industri pharmaceut
johnson johnson
subsequ advanc mani manag
posit drug devic divis johnson
johnson along manageri post novarti give
broad experi need run massiv health
conglomer first major test gorski leadership
billion acquisit orthoped devic firm
synth larg driven gorski head
johnson johnson devic unit believ
acquisit ad import exposur emerg market
trauma devic appear small
impact valuat price paid synth larg
account
increment benefit gain
acquisit second major test gorski recent
complet actelion deal skeptic
abl creat much valu sharehold due high
acquisit price rel fair valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
side effect appeal reduc cost oct
expect recent billion rule johnson
johnson regard side effect neurosci drug
risperd fall significantli appeal dont expect
chang fair valu estim base rule
dont factor materi payment relat litig
risperd side effect discount cash flow
valuat model mani similar case alreadi
settl thrown prescrib label
risperd call signific side effect includ
gynecomastia male breast enlarg side effect
led recent juri rule expect recent rule
fall significantli base label drug
highlight side effect well similar case reach
much smaller settlement thrown legal
process johnson johnson face larger
litig risk around past opioid drug market
potenti side effect talc powder dont believ
overal legal challeng pose major threat
compani wide moat factor close
billion litig charg opioid talcum powder
legal case case could take sever year
oklahoma opioid case goe expect
appeal process lead lower payment aug
one first state opioid case oklahoma judg
rule johnson johnson award state
million well billion state
seek damag amount lower mani
expect still plan appeal case expect
appeal process take sever year appeal
believ amount fall lower believ
larg provid appropri market support around
opioid drug sale overal expect chang
fair valu estim moat rate compani base
rule continu model billion total
opioid litig cost
next step opioid litig process includ
state case like long appeal process follow
oklahoma rule expect ohio case repres
next import step determin magnitud
overal opioid litig lack earli settlement
opioid drugmak ohio like purdu settlement
oklahoma suggest state could less sympathet
plaintiff also regardless outcom ohio
expect rule similarli appeal set
process like take sever year complet
strong balanc sheet like entic mani
plaintiff target firm within opioid litig
landscap plaintiff target sever industri
firm potenti caus addict overdos
power drug howev hold one
strongest balanc sheet robust stream cash
flow make larger target mani
smaller specialti drug firm carri much weaker
repres small fraction overal prescript
opioid sale less state paid opioid prescript
believ deep pocket made firm
larger target opioid sale would suggest
across busi segment drug pipelin look solid
expect chang fair valu johnson
 johnson firm report second-quart result
larg line expect adjust
divestitur slightli ahead consensu expect
continu view stock fairli valu
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
factor close billion litig charg
opioid talcum powder legal case firm
wide moat look intact especi follow research
develop updat drug unit show mani
promis molecul area unmet medic need
enabl strong price power
quarter three major segment post
adjust oper growth low- mid-single-digit
rang drug unit show leadership growth
quarter rel strength segment
robust seen past quarter patent loss
weigh divis especi cancer drug zytiga
nevertheless drug unit abl post oper
growth expect continu steadi growth
divis next sever year led recent launch
oncolog immunolog drug also firm recent
pipelin updat may increas convict
divis led us increas fair valu estim
per share pipelin asset track well
like focu oncolog rare diseas
drug price strong develop timelin
outsid drug franchis smaller divis
devic consum product post adjust
growth respect expect divis growth
continu trend magnitud next sever
year potenti wildcard devic segment
robot develop could acceler growth
rel secret initi lead
us project conserv growth assumpt
new product
look deeper pipelin continu advanc
drug portfolio expand indic current
market drug bring new drug market
complet review pipelin pleas see annual
drug pipelin report moat remain secur innov
counter price gener headwind
opioid case cost look manag may
johnson johnson stock face pressur
on-going legal case oklahoma regard firm
histor sale market practic opioid drug
 js ultim financi liabil uncertain
factor close billion legal cost relat past
opioid drug sale continu view compani fair
valu estim expect case affect
firm wide moat howev recent settlement
purdu pharma relat opioid
drug sale concern total payment
million oklahoma mani similar case
reach court yet
expect johnson johnson make case
opioid drug market clearli respect drug
label compani key opioid drug durages
nucynta carri label highlight addict qualiti
drug signific risk risk
highlight expect less liabil compani also
believ compani larg market opioid drug
accord label off-label market fallen
significantli last decad major settlement
relat off-label market antipsychot drug close
decad ago despit content like
market opioid drug correctli expect close
billion relat legal cost drug firm tend litig
type case includ appeal sever year
eventu offer settlement
 provid solid updat pharmaceut busi
may johnson johnson host pharmaceut
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
complet review pipelin pleas see annual
drug pipelin report moat remain secur innov
counter price gener headwind
updat invest commun highlight key
drug pipelin led us increas fair valu
estim stock continu trade
close fair valu suggest growth prospect
incorpor current stock price increas
visibl compani pipelin also strengthen
convict compani wide moat rest larg
firm abil develop innov new drug
 highlight key late-stag drug reach
market within next five year heavi focu
oncolog key late-stag drug bode well
compani price power scientif advanc
quicker develop time typic cancer
drug within cancer drug view egfr drug
multipl myeloma drug
well posit growth
drug compet drug
strong efficaci early-stag data look compel
drug gene therapi retin
drug depress drug vaccin
rsv notabl multipl sclerosi drug ponesimod
remain develop highlight drug
key drug potenti billion annual sale
outsid new drug launch pipelin also includ
develop new indic exist drug six-
month dose version invega schizophrenia new
indic tremfya psoriat arthriti crohn diseas
ulcer coliti expand cancer label darzalex
imbruvica erleada balversa drive futur growth
import drug drug face
increas competit expand label help
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
